Status:
RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Lead Sponsor:
Greenwich LifeSciences, Inc.
Conditions:
Breast Cancer
Eligibility:
All Genders
18-100 years
Phase:
PHASE3
Brief Summary
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk f...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
August 11 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT05232916
Start Date
August 11 2022
End Date
December 1 2026
Last Update
October 3 2025
Active Locations (161)
Enter a location and click search to find clinical trials sorted by distance.
1
Tucson Medical Center HealthCare - Tucson-Rudasill
Tucson, Arizona, United States, 85704
2
Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center
Fullerton, California, United States, 92835
3
University of California San Diego - Moores Cancer Center
La Jolla, California, United States, 92093
4
University of Southern California - Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033